 |
Text Search: |
ExperienceCandace Summerford joined the firm in 2003 as a patent specialist. She focuses her practice on patent portfolio management and the preparation and prosecution of patent applications in the biotechnology field. She also assists in the preparation of patentability and infringement opinions. Dr. Summerford has extensive experience in molecular biology, virology, cell biology, pharmacology, and biochemistry. Her scientific research focused on studying the initial stages of viral infection. Her research also involved the development of viral vectors for use in gene therapy. Dr. Summerford earned her Ph.D. at the University of North Carolina, Chapel Hill, from the department of Pharmacology where she graduated with Honors. Her doctoral thesis work included the identification of viral receptors for Adeno-Associated Virus (AAV). During her doctoral studies in Pharmacology, Dr. Summerford was recognized with the Hoechst-Celanese Corporation/University of North Carolina at Chapel Hill Academic Excellence Award. Prior to her Ph.D. work, she worked in the field of molecular biology and established a method for expressing hemoglobin in bacterial cells. Dr. Summerford’s postdoctoral work, which was performed with Dr. Richard Mulligan at Harvard Medical School, involved studying the mechanisms of Moloney Murine Leukemia Virus (Mo-MLV), Spleen Necrosis Virus (SNV), and Lentiviral infection.
Dr. Summerford has presented her work in scientific journals and at international meetings. She has published many reviews in her field and holds several patents related to her research. AdmissionsDr. Summerford is admitted to practice before the United States Patent and Trademark Office. Journal Articles and Reviews“Adeno-associated virus, Basic Biology and Vector Applications” (with J.S. Bartlett and R.J. Samulski), Progress in Gene Therapy: Basic and Clinical Frontiers, 85–138 (The Netherlands: VSP Publishers, 2000). “Adeno-associated viral vectors and successful gene therapy, the gap is closing” (with J.S. Bartlett and R.J. Samulski), Gene Therapy and Regulation 1 (1) (2000): 1–24. “Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield” (with S. Zolotukhin, B.J. Byrne, E. Mason, I. Zolotukhin, R.J. Samulski, and N. Muzyczka), Hum. Gene Ther. 6 (6) (1999): 973–985. “Viral receptors and vector purification: new approaches for generating clinical grade reagents” (with R.J. Samulski), Nature Medicine 5 (5) (1999): 587–588. “A role for αvβ5 integrin in adeno-associated virus type 2 (AAV-2) infection” (with J.S. Bartlett and R.J. Samulski), Nature Medicine 5 (1) (1999): 78–82. “Adeno-associated viral vectors for gene therapy” (with R.J. Samulski), Biogenic Amines 14 (1998): 451–475. “Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions” (with R.J. Samulski), J. Virol. 72 (1998): 1438–1445. “Bacterial expression of Scapharca dimeric hemoglobin: A simple model system for investigating protein cooperativity” (with A. Pardanani, A.H. Betts, A.R. Poteete, G. Colotti, and W.E. Royer), Protein Engineering 8 (6) (1995): 593–599. EducationUniversity of North Carolina at Chapel Hill, Ph.D, Pharmacology |
|||
 |
Boston
•
Chicago
•
Los Angeles
•
London
•
New York
•
Paris
Rochester • San Francisco • Shanghai • Silicon Valley • Washington • Albany Buffalo • Long Island • Manchester • Palm Beach Gardens • Providence Disclaimer | Nixon Peabody International | © 2010 Nixon Peabody LLP |
|||
